Martin and Harris Laboratories Ltd
| Market Cap | ₹340Cr. | Stock P/E | 8.4 |
| Current Price | ₹1450 | Book Value | ₹1581.7 |
| Lot Size | 100 | 52W Low | ₹ |
| 52W High | ₹ | Demat Account | NSDL\CDSL |
| EPS | 101.17 | ISIN | INE03VV01015 |
| Debt to Equity | 0.01 | Valuation | ⭐⭐⭐⭐⭐ |
| Face Value | 10 | No. of Shares | 0.4 |
Current Price : ₹1450
Price History
Description
| Buy Price | Minimum Quantity | Amount |
|---|---|---|
| ₹ 1435.5 | 100 | ₹ 143550 |
| Sell Price | Minimum Quantity | Amount |
|---|---|---|
| ₹ 1450 | 100 | ₹ 1,45,000 |
Company Overview:
Company Overview : Incorporated in 1993 at Gurgaon, Martin and Harris Laboratories Ltd is a pharmaceutical and a manufacturer of botanical products. The company is a part of India’s largest and oldest business conglomerate i.e. Apeejay Group. The company also invests its money in various avenues such as mutual funds, listed shares, and unlisted shares, and so on to get great returns.
Martin and Harris Laboratories Ltd. operates state-of-the-art manufacturing facilities located at prime locations of the country in order to serve our domestic & International markets. These units have a multi-decade experience of manufacturing different complex dosage forms and specialty formulations.
Announcement and News
Financial Data (IN CR.)
| YEAR | 2024 | 2023 | 2022 |
|---|---|---|---|
| NET SALES | 146.1 | 205.2 | 186.3 |
| TOTAL INCOME | 180.4 | 229.2 | 212.1 |
| NET PROFIT | 40.4 | 68.1 | 70.2 |
| SHAREHOLDERS FUND | 632.1 | 593.3 | 542.6 |
| TOTAL ASSETS | 662 | 614.7 | 542.6 |
| EPS | 101.17 | 170.34 | 175.57 |
Profit and Loss (IN CR.)
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Revenue | 186 | 205 | 146 |
| Cost Of Material Consumed | 50 | 47 | 41 |
| Gross Margin | 73.12 | 77.07 | 71.92 |
| OPM | 37.63 | 35.12 | 17.81 |
| Other Income | 26 | 24 | 34 |
| Other Expenses | 47 | 61 | 55 |
| Depreciation & Amortization | 3 | 4 | 5 |
| Profit before tax | 93 | 92 | 55 |
| Net Profit Margin | 37.63 | 33.17 | 27.4 |
| EPS in Rs | 175.44 | 170.43 | 100.25 |
| Finance Cost | 0.15 | 0 | 0.6 |
Balance Sheet (IN Cr.)
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Share Capital | 3.99 | 3.99 | 3.99 |
| Reserves | 523 | 589 | 628 |
| Borrowings | 5 | 4 | 8 |
| Other Liabilities | 7.01 | 8.01 | 5.01 |
| Total Liabilities | 543 | 615 | 662 |
| Fixed Assets | 13 | 15 | 18 |
| CWIP | 0.4 | 3 | 0 |
| Investments | 373 | 62 | 70 |
| Other Assets | 132.6 | 515 | 542 |
| Total Assets | 543 | 615 | 662 |
Shareholding Pattern
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Chang Investchem Private Limited | 37.53% | 37.53% | 37.53% |
| Aessen Private Limited | 20.51% | 20.51% | 20.51% |
| Acme Network S.A | 20.07% | 20.07% | 20.07% |
| Others | 21.88% | 21.88% | 21.88% |